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Abstract
Background: It has been shown that free DNA circulates in serum plasma of patients with cancer
and that at least part is present in the form of oligo- and monucleosomes, a marker of cell death.
Preliminary data has shown a good correlation between decrease of nucleosomes with response
and prognosis. Here, we performed pre- and post-chemotherapy determinations of serum
nucleosomes with an enzyme-linked immunosorbent assay (ELISA) method in a group of patients
with cervical cancer receiving neoadjuvant chemotherapy.
Methods: From December 2000 to June 2001, 41 patients with cervical cancer staged as FIGO
stages IB2-IIIB received three 21-day courses of carboplatin and paclitaxel, both administered at
day 1; then, patients underwent radical hysterectomy. Nucleosomes were measured the day before
(baseline), at day seven of the first course and day seven of the third course of chemotherapy.
Values of nucleosomes were analyzed with regard to pathologic response and to time to
progression-free and overall survival.
Results: All patients completed chemotherapy, were evaluable for pathologic response, and had
nucleosome levels determined. At a mean follow-up of 23 months (range, 7–26 months), projected
progression time and overall survival were 80.3 and 80.4%, respectively. Mean differential values of
nucleosomes were lower in the third course as compared with the first course (p >0.001). The
decrease in the third course correlated with pathologic response (p = 0.041). Survival analysis
showed a statistically significant, better progression-free and survival time in patients who showed
lower levels at the third course (p = 0.0243 and p = 0.0260, respectively). Cox regression analysis
demonstrated that nucleosome increase in the third course increased risk of death to 6.86 (95%
confidence interval [CI 95%], 0.84–56.0).
Conclusion:  Serum nucleosomes may have a predictive role for response and prognostic
significance in patients with cervical cancer patients treated with neoadjuvant chemotherapy.
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Background
The search for molecular markers to predict response to
treatment and prognosis in patients with cancer has
always occupied a major role in cancer research. To date,
glycoproteins, polypeptides, or other macromolecules
such as CEA, CAI5-3, AFP, β HGC, etc. – that are deter-
mined by biochemical methods – have a definitive, albeit
modest, role for patient management in some tumor
types [1,2].
Knowledge of tumor biology and availability of molecular
biology techniques have allowed testing of a vast array of
potential molecular markers. Among these, those focused
on apoptosis have gained considerable attention because
of the major role that cell death plays in tumorigenesis
and response to therapy [3,4].
It is well-known that free or extracellular DNA circulates
in serum/plasma of patients with cancer and in healthy
individuals [5]. Such an observation has been raised of
late and has focused increased attention particularly on
the field of tumor markers. In patients with cancer, there
is often a correlation between tumor load and amount of
free DNA in circulation [6]. Because part of this DNA
exists in the form of oligo- and mononucleosomes, the
cell death detection plus -ELISA- kit (Boehringer Man-
nheim) that is based on a quantitative sandwich-enzyme-
immunoassay-principle using mouse monoclonal anti-
bodies directed against DNA and histones, respectively,
were developed as an in vitro test; nonetheless, this subse-
quently has been applied to quantification of oligo and
mononucleosomes in tumors [7] and in the plasma/
serum [8] of cancer patients. We recently demonstrated in
mice and humans that at least part of nucleosomes in cir-
culation originates from tumor cells, that the early rise of
nucleosomes observed in patients undergoing chemo-
therapy is the consequence of the tumor apoptosis
induced by chemotherapy, and that due to an efficient
mechanism of depuration a lower level of nucleosomes
post-chemotherapy indicates a favorable tumor response
in patients with cervical cancer [9].
To date, the majority of studies that have evaluated the
nucleosome level pre- and post-therapy with the enzyme-
linked immunosorbent assay (ELISA) method have been
performed on a small and rather heterogeneous group of
patients with regard to tumor type and chemotherapy
schedule [10,11]. Consequently, the potential value of
serial determination of serum nucleosomes to predict
response to therapy and prognosis remains to be investi-
gated. In this study, we have addressed this issue by per-
forming pre- and post-chemotherapy analyses of serum
nucleosomes in a homogeneous group of patients with
locally advanced cervical cancer treated with paclitaxel
and carboplatin as neoadjuvant therapy followed by
surgery.
Methods
Forty one untreated patients with histologic diagnosis of
cervical carcinoma and FIGO staged as IB2-IIIB were stud-
ied. Patients needed to meet the following inclusion crite-
ria: 1) aged between 18 and 70 years; 2) performance
status 0–2 according to Word Health Organization
(WHO) criteria; 3) normal hematological, renal, and
hepatic function according to standard parameters; 6) a
normal chest x-ray, and 7) signature on written informed
consent. Exclusion criteria included 1) severe systemic or
uncontrolled disease (infection, central nervous system,
metabolic, etc.) that precluded use of chemotherapy, 2)
pre-existing neuropathy due to any cause, 3) pregnancy
and lactation, 4) mental illness, and 5) previous or con-
comitant malignancies (exception, melanoma skin can-
cer). The protocol was approved by the regulatory boards
of the Instituto Nacional de Cancerología (INCan) in
Mexico City.
Treatment. Treatment consisted of carboplatin at a dose of
6 area under the curve (AUC) diluted in 500 mL of 5%
glucose administered over 1 h followed by paclitaxel at
175 mg/m2 administered over 3 h, both drugs on day l; a
total of three 21-day courses were administered. Com-
plete blood cell counts and biochemical profiles were per-
formed at days 14 and 21 of each cycle. After neoadjuvant
chemotherapy, patients were submitted to radical hyster-
ectomy. Adjuvant post-operative chemoradiation with cis-
platin was performed in all cases with positive surgical
margins, one or more positive pelvic lymph node, and in
patients with disease in parametria (all high-risk factors
for recurrence) [12], as well as in cases whose residual dis-
ease contained vascular or lymphatic permeation and/or
deep invasion into the middle or internal thirds of the cer-
vical stroma (both intermediate-risk factors for recur-
rence) [13].
Blood sampling for nucleosome measurements. The day
prior to beginning the first course of chemotherapy, a
sample of 6 mL of blood was drawn from the patient's
arm and centrifuged within the next h at 1,500 g for 20
min to obtain serum. Subsequently, we added 10 rnM
EDTA (pH8) to the serum and samples were stored at -
20°C until analysis. The same procedure was performed
for taking and processing samples at day 7 of the first
course of chemotherapy and at day 7 of the third course of
chemotherapy (hereafter referred as the first and third
courses).
Analysis of nucleosomes by ELISA. This assay was carried
out with the cell death detection kit plus -ELISA- (Roche)
as follows: 20 µL of serum samples (diluted 1:4 withBMC Cancer 2005, 5:65 http://www.biomedcentral.com/1471-2407/5/65
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incubation buffer) were placed into a streptavidin-coated
microtiterplate and incubated with a mixture of anti-his-
tone-biotin and anti-DNA-POD for 2 h at 15–25°C. Anti-
bodies bind to the histones and DNA of nucleosomes and
fix the immunocomplexes to the microtiterplates by the
streptavidin-biotin interaction. After the incubation
period, unbound antibodies are removed by washing with
incubation buffer; then, the ABTS (2,2-Azino di-3-ethyl-
benzthiazolin-sulfonate) solution is added for 30 min.
Incubation of the retained POD-linked complexes with
ABTS as substrate permits the spectrophotometrical quan-
tification of the nucleosomes at 405 nm. As positive con-
trol, we used the complex DNA-histone provided in the
kit and as negative control, the substrate solution only.
We constructed a standard curve with serial dilutions of
apoptotic material ranging from 3,500 arbitrary units
(AU) to 200. All determinations were performed by dupli-
cate, and then the values of the double absorbance meas-
urements of the samples were averaged. Afterward,
background value of the immunoassay from each of these
averages was subtracted and final values were expressed as
AU; interassay variability was 10%.
Tumor response criteria and efficacy assessment.
Response to neoadjuvant chemotherapy was evaluated
pathologically in the surgical specimens and classified as
complete or partial. Complete response was considered
when there was no evidence of tumor cells or when there
was residual microscopic disease in absence of positive
pelvic or para-aortic lymph nodes, disease in parametria,
positive surgical margins, vascular and/or lymphatic per-
meation, or deep invasion into the middle or internal
thirds of the cervical stroma. Partial pathologic response
was considered with any macroscopic residual, or any
microscopic residual plus at least one high-risk and/or
intermediate-risk factor for recurrence. Time to progres-
sion was considered from the date that chemotherapy
began until the date of confirmed progressive and/or
recurrent disease, whereas overall survival was considered
from date of diagnosis until the date of patient's death.
Statistical analysis. Baseline level of nucleosomes was
compared with those obtained at first and third courses of
chemotherapy using the paired t  test. Patients were
divided into two groups depending on the differential val-
ues of nucleosomes above and below the median to cor-
relate with pathologic response using the chi square test.
Survival analysis for time to progression and overall sur-
vival was performed using the Kaplan-Meier method [14].
Differences in survival between groups were analyzed by
the log-rank method [15]. Cox proportional hazards
regression analysis was used to assess prognostic signifi-
cance of a number of covariates in a multivariate setting
[16]. Two-tailed probability values of "conventional" 0.05
or less were considered significant.
Analysis was performed with SPSS for Windows version
10 (SPSS, Inc., Chicago, IL, USA, 1999).
Results
Patient characteristics
A total of 41 patients were studied. Characteristics of these
patients are shown in Table 1. Median patient age was 45
years (range, 24–67 years); the majority of patients had
squamous tumors (8 %) and were staged IB2-IIB(84%).
Serum nucleosomes
We evaluated nucleosome levels in all 41 patients before
(baseline) and post-treatment at first and third chemo-
therapy courses. As shown in Figure 1, mean (CI 95%)
baseline level was 1,085 AU (median, 825) with a range
Table 1: Patient characteristics
Number 41
Age (years) 45 (24–67)
Clinical stage
IB2-IIB 34 (84)
IIIB 7 (16)
Tumor size (cm2)
<30 22 (53)
>30 19 (47)
Histology
Squamous 33 (81)
Adeno/adesq 8 (19)
Nucleosome values Figure 1
Nucleosome values. Expressed as mean values and CI 95%, 
had a mild increase in the first course to decrease thereafter, 
however, these differences were not statistically significant.
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from 419–2,980 AU. Measurement at the first chemother-
apy course showed a mean of 1,120 AU (CI 95%),
(median, 891) ranging from 499–3,200 AU, and at the
third course there was a mean of 978 AU (CI 95%)
(median, 897) with a range of 471–2,930 AU. There were
no statistically significant differences as compared with
baseline values or between these. To further evaluate
nucleosome behavior during treatment, differential val-
ues of nucleosomes were calculated between baseline and
first and third courses. In the first course, levels dimin-
ished in 20 patients to a mean of -411 (standard deviation
[SD] 692) and a median of -170 AU, whereas values
increased in 21 patients with a mean of 561 (SD, 492) and
median of 417 AU. On the other hand, during the third
chemotherapy course the mean value for the 20 patients
in whom values decreased was -611 (SD, 628) and the
median of -327 AU, while in the remaining patient values
mean increase was 430 (SD, 462) with a median of 217
AU. The paired t  test was statistically significant (p
<0.0001).
Pathologic response and clinical outcome
Induction chemotherapy was well tolerated. A total of 123
cycles were administered, of which only two were delayed
for 1 week. Most common toxicities were nausea/vomit-
ing and neuropathy, which were mainly grades 1–2. There
were no cases of leukopenia grade 3 but neutropenia
grades 3 and 4 were present in 12 and 3% of the courses,
respectively. Other toxicities were mild and uncommon.
All patients completed the three chemotherapy courses
and underwent radical hysterectomy. Surgical specimen
analysis showed complete pathologic response in 16 cases
(39%), while partial pathologic response was found in 25
of 41 patients (61%). At a mean follow-up of 23 months
(range, 7–26 months), projected progression time and
overall survival were 80.3 and 80.4%, respectively.
Correlation of nucleosome levels with pathologic response
For establishing associations between pathologic
response and prognosis, patients were divided into two
groups depending on differential values of nucleosomes
above and below the median. Nucleosome levels at first
chemotherapy course showed no statistically significant
correlation with response, (χ 2 test, p = 0.160) (Table 2).
On the other hand, there was a statistically significant –
albeit marginal – correlation between response and nucle-
osome levels measured at the third course, and there were
11 complete responses among the 20 patients who had
lowered nucleosomes and 16 partial responses in patients
with elevated nucleosomes (χ 2 test, p = 0.041) (Table 3).
Correlation of nucleosome levels with clinical outcome
Nucleosome levels at first chemotherapy course failed to
correlate with outcome. Contrariwise, survival analysis
conducted with values obtained at the third course
showed a statistically significant better time to progres-
sion and overall survival in patients who demonstrated
lower levels (p = 0.0243) and p = 0.0260, respectively)
(Figure 3). Clinical stage and tumor size were also ana-
lyzed. Earlier staged (IB2-IIB) patients had longer time to
progression and survival as compared with patients staged
at IIIB (p = 0.0164 and p = 0.0105, respectively), whereas
patients with smaller tumors had longer time to progres-
sion and survival (p = 0.0096, and p = 0.0089, respec-
tively). In addition, the status of complete pathologic
response showed a trend for better time to progression
and survival times (p = 0.0998 and p = 0.0953, respec-
tively) (data not shown).
We assessed the prognostic significance of a number of
covariates in a multivariate setting. Covariates considered
for inclusion were nucleosome values at third course,
stage, tumor size, and pathologic response. A forward
selection procedure was used to find the combination of
Table 2: Correlations of nucleosome levels in the first course and response to chemotherapy
Complete response Partial response p value
Nucleosome decrease 10 10
Nucleosome increase 6 15 p = 0.160
Table 3: Correlations of nucleosome levels in the third course and response to chemotherapy
Complete response Partial response p value
Nucleosome decrease 11 9
Nucleosome increase 5 16 p = 0.041BMC Cancer 2005, 5:65 http://www.biomedcentral.com/1471-2407/5/65
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pairs of covariates that were significant or that showed a
trend (p <0.1) in survival. Cox regression analysis of all
patients showed that nucleosome levels and tumor size
were significant prognostic factors for survival. Response
rate (RR) showed that nucleosome increase in the third
course increased risk of death to 6.86 (CI 95%, 0.84–
56.04), whereas a tumor size >30 cm2 increased risk of
death to 9.08 (CI 95%, 1.11–74.20) (Table 4).
Discussion
The majority of anticancer agents in use at present were
developed using empirical screens designed to identify
Kaplan-Meier estimates of survival at a mean follow-up of 23 months (range, 7–26 months) according to nucleosome values  determined in the third chemotherapy course (p = 0.0260) Figure 3
Kaplan-Meier estimates of survival at a mean follow-up of 23 months (range, 7–26 months) according to nucleosome values 
determined in the third chemotherapy course (p = 0.0260). Time to progression-free survival interval was also statistically sig-
nificant longer in patients who experienced decreased nucleosomes.
Table 4: Cox model for survival
Variable SE RR CI 95% p value
Nucleosome in third course Decrease vs Stable 1.07 6.86 0.84–56 0.072
Tumor size <30 cm2 vs >30 cm2 1.07 9.08 1.10–74 0.040
SE, standard error; RR, response rate. CI 95%, 95% confidence interval.
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agents that selectively kill tumor cells. However, until
recently pathologists noticed that radiation and chemo-
therapy can induce cell death with the morphologic fea-
tures of apoptosis [17], although the significance of these
observations was not widely appreciated. Currently, it is
well-established that anticancer agents induce apoptosis
and that disruption of apoptotic programs can reduce
treatment sensitivity [18]. This connection between
response to treatment and apoptosis has led to evaluation
of apoptosis levels by diverse methods the levels before or
during treatment with variable results. While single or
baseline levels of apoptosis, or key pro- or anti-apoptotic
gene products, yield mixed results in its prognostic signif-
icance [7,19-25], evaluation of the treatment-induced
apoptotic effect has shown to be more useful [26,27];
however, this is associated with the risk and discomfort of
repeated biopsies. In this scenario, measurement of serum
nucleosomes by ELISA, a simple and non-invasive test,
has facilitated the testing of its prognostic significance in
cancer treatment.
Previous studies of serum nucleosomes in patients with
cancer have shown that high heterogeneity in baseline lev-
els of nucleosomes among the different types of cancer
and even among patients with the same tumor type. Our
present data from a homogeneous population of patients
with cervical cancer confirm these observations: values
ranged from 419–2,980 AU. These values are nevertheless
very similar to those found by our group in a previous
study in patients with cervical cancer similar clinical
stages, which ranged from 627–2,313 AU [9]. On the
other hand, we found no correlation of baseline levels
with clinical-pathologic factors. It appears that this corre-
lation could be tumor type-specific, as reported by Hold-
enrieder et al., who showed a highly significant
correlation between stage and serum nucleosomes in
colon but not in breast carcinoma [28].
To evaluate the potential prognostic significance of serum
nucleosomes, it is important to choose adequate evalua-
tion time points that would reflect the proapoptotic effect
of chemotherapy; to date, optimal time points for meas-
urement have not been established. Holdenrieder et al.
analyzed a total of 42 patients (colorectal, lung, and lym-
phoma) receiving primary adjuvant of second-line chem-
otherapy with a variety of agents and schedules
(administration in 1–5 days). Despite such heterogeneity
in the study, a pattern of nucleosome increase within the
first 3 days to a subsequent nucleosome decrease in the
treatment-free period emerged, as well as correlation of
post-treatment levels of nucleosomes with response [10].
Similar data was reported by Kuroi et al., in 18 patients
with recurrent breast carcinoma undergoing treatment
with docetaxel every 3–4 weeks; these authors found a sta-
tistically significant correlation between decrease in nucle-
osomes and response. In addition, they evaluated the
kinetics of nucleosomes before and 72 h thereafter in four
patients who received single-agent docetaxel; in this
instance, the authors found a peak of nucleosomes at 24
h and a decrease at 72 h [11]. To the contrary, we previ-
ously reported that in patients with cervical cancer receiv-
ing oxaliplatin, gemcitabine at day 1 the rise occurred
within the first hours to decrease at 24 h in the responding
patients [9]. Based on these data, we decided to evaluate
here nucleosomes at day 7 of the first and third courses of
treatment with carboplatin and paclitaxel. At such time
points, it could be expected that no significant drug levels
would be in circulation and that therefore, nucleosomes
would reflect tumor mass or activity as the maximum level
of cytotoxicity could be attained in the days prior to
measurement, as demonstrated in a murine model of
tumors treated with platinum [29] or paclitaxel [30].
Interestingly, as a whole there were no nucleosome reduc-
tions either in the first course (mean baseline, 1,085 vs.
1,120) or at the third treatment course (baseline, 1,085 vs.
978). However, differential levels showed a higher
decrease in the third than in the first course as compared
with the baseline (-611 vs. -411, respectively). These
results would suggest that as a whole, tumor reduction
induced by one chemotherapy course was insufficient to
produce significant reduction in nucleosome levels in this
patient population receiving the carboplatin plus paclit-
axel combination.
On the other hand, Tables 2 and 3 show that nucleosomes
at the third – but not at the first – course correlated with
pathologic response. This is illustrated in Figure 2, which
shows a trend for lower levels of nucleosomes in both first
and third courses in patients who achieved complete
response with regard to those who did not, suggesting that
these tumors were sensitive to chemotherapy and that
they failed to develop resistance during subsequent thera-
peutic courses.
Our results to date demonstrate that decrease in serum
nucleosomes during chemotherapy treatment – although
marginally – correlates with response under these experi-
mental conditions. To investigate whether the kinetics in
nucleosome levels possesses prognostic significance, we
analyzed time to progression-free survival and overall
survival. Results showed that while nucleosome levels at
the first cycle failed to correlate with time to progression
and survival, third-cycle levels did correlate with both
parameters; on the other hand, earlier stages (IB2-IIB) and
smaller tumors also showed longer time to progression
and survival. Interestingly, neither time to progression nor
survival were correlated with pathologic response. To
investigate which variables maintained their prognostic
significance for survival, a Cox proportional hazard
model was undertaken using pairs of covariates to ascer-BMC Cancer 2005, 5:65 http://www.biomedcentral.com/1471-2407/5/65
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tain which of these pairs better predicted outcome. Nucle-
osomes determined at the third course and tumor size
emerged as statistically significant; however, these results
should be considered with caution, as confidence inter-
vals were very wide, perhaps as a result of small sample
size and small number of events.
The biological meaning of circulating nucleosomes and
the factors that govern their production and clearance
from the body are yet to be understood. A body of exper-
imental evidence demonstrates that in mice, apoptosis
develops rapidly, within hours, after cytotoxic treatments
and that it is dose-dependent [31]; moreover, the extent of
apoptosis is higher with the first treatment course than
after subsequent doses [30]. In this study, we found that
nucleosomes after the first course lowered to a lesser
degree than after the third cycle. This finding may reflect
either that a single measurement after the initial cycle is
not sufficient and would require repeated measurements
during the first course of chemotherapy, as recently
reported by Holdenrider et al. These investigators found
that the area under the curve of nucleosomes during days
1–8 of the first chemotherapy cycle carried the strongest
prognostic impact in patients with lung cancer [32].
Our finding on the correlation between nucleosome levels
at the third course with prognosis may suggest that the
kinetics of circulating nucleosomes may not only reflect
the immediate, chemotherapy-induced debulking effect,
but that other factors such as amount and/or activity of
Nucleosome value distribution according to response (expressed as mean and CI 95%) Figure 2
Nucleosome value distribution according to response (expressed as mean and CI 95%). A clear trend for decrease in both 
measurements is shown in responding patients.
Pathological Complete Response
Yes No
1800
1600
1400
1200
1000
800
600
Baseline
Cycle 1
Cycle 3
(
m
U
)
M
e
a
n
N
u
c
l
e
o
s
o
m
e
l
e
v
e
l
(
9
5
%
C
I
)BMC Cancer 2005, 5:65 http://www.biomedcentral.com/1471-2407/5/65
Page 8 of 9
(page number not for citation purposes)
serum nucleases [33], efficiency of nucleosome clearing
from circulation [34,35], and perhaps the macrophage
number and function [36] may also influence the behav-
ior of nucleosomes, which in turn may have possess on
their own an effect on tumor-host interactions that influ-
ences the patient's prognosis. This is suggested by data
demonstrating that chromatin fragments impair the natu-
ral killer-mediated cytotoxicity of tumor cells [37].
Conclusion
Serum nucleosome level as determined in the third course
of neoadjuvant chemotherapy in patients with cervical
cancer was marginally related with tumor response and
survival. Our findings, along with those reported by other
authors on diverse tumor types, suggest that circulating
nucleosome measurements could be a useful predictive
and/or prognostic factor in the management of patients
with cancer. Further studies are needed to better define
not only the predictive/prognostic role of circulating
nucleosomes in cancer, but also their potential participa-
tion in their own right in response to therapy.
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